Thursday, December 14, 2017 3:27:36 PM
Isodiol International Inc. Initiates Implementation of Blockchain Technology
VANCOUVER, British Columbia, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce the Company has initiated Phase 1 of implementing cryptocurrency through BitPay, a global blockchain payments technology platform.
Founded in 2011, BitPay has succeeded in making payments faster and more secure at a low cost, while making it easier for businesses to accept bitcoin payments. BitPay’s bitcoin payment experience is used by hundreds of thousands of users around the globe.
“The Isodiol customer experience is always a priority for us and accepting bitcoin seemed to be a natural implementation, as we want to ensure that our customers have choices as to how they shop and ultimately have the best experience possible,” said Marcos Agramont, CEO of Isodiol. “In Phase 2 of the implementation, which takes place in the first quarter of 2018, we anticipate cryptocurrency acceptance across all of Isodiol’s family of brands.”
For more information on Isodiol, please visit www.isodiol.com
For more information on BitPay, please visit www.bitpay.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM